___

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2014 update: a re- port from the American Heart Association. Cir- culation 2014; 129: 28-292.
• Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cho- lesterol transport. Circ Res 2005; 96: 1221-32.
• Yasuda T, Ishida T, Rader DJ. Update on the role of endothelial lipase in high-density lipop- rotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 2010; 74: 2263-70.
• Ross R. Atherosclerosis -an inflammatory disea- se. N Engl J Med 1999; 340:115-26.
• Tedgui A, Mallat Z. Cytokines in atherosclero- sis: pathogenic and regulatory pathways. Phy- siol Rev 2006; 86: 515-81.
• Kanda T, Takahashi T. Interleukin-6 and cardi- ovascular diseases. Jpn Heart J 2004; 45: 183
• Ji QW, Guo M, Zheng JS, et al. Downregulation of T helper cell type 3 in patients with acute co- ronary syndrome. Arch Med Res 2009; 40: 285-
• Kilic T, Ural D, Ural E, et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. He- art 2006; 92: 1041-6.
• Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: -2.
• Libby P, Ridker PM. Inflammation and athe- rosclerosis: role of C-reactive protein in risk as- sessment. J Med 2004; 116: 9-16.
• Okrainec K, Banerjee DK, Eisenberg MJ. Coro- nary artery disease in the developing world. Am Heart J 2004; 148: 7-15.
• Yasuda T, Ishida T, Rader DJ. Update on the role of endothelial lipase in high-density lipop- rotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 2010; 74: 2263-70.
• Ishida T, Choi SY, Kundu RK, et al. Endothelial lipase modulates susceptibility to atherosclero- sis in apolipoprotein-E-deficient mice. J Biol Chem 2004; 279: 45085-92. van der Giet M, Tolle M, Pratico D, et al. Inc- reased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease. J Mol Med 2010; 88: -83.
• Zhang J, Yu Y, Nakamura K et al. Endothelial lipase mediates HDL levels in normal and hy- perlipidemic rabbits. J Atheroscleros Thrombos. ; 19: 213-26. Ko KW, Paul A, Ma K, Li L. Chan L. Endothe- lial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice. J Lipid Res 2005; 46: 2586-94.
• Sugita T, Watarida S, Katsuyama K, Nakajima Y, Yamamoto Y, Mor A. Interleukin-10 con- centration in children undergoing cardiopulmo- nary bypass. J Thorac Cardiovasc Surg 1996; : 1127-8.
• Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin-10 regulation in- normal subjects and patients with asthma. J Al- lergy Clin Immunol 1996; 97: 1288-96.
• Hansson G, Robertson AL, Soderberg-Naucler C. Inflammation and Atherosclerosis. Annu Rev Pathol Mech Dis 2006; 1: 297-329.
• Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: 17-24.
• Mallat Z, Heymes C, Ohan J, Faggin E, Lesèche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques. Arte- rioscler Thromb Vasc Biol 1999; 19: 611- 16.
• Galkina E, Ley K. Immune and ınflammatory mechanisms of atherosclerosis. Ann Rev Immu- nol 2009; 27: 165-97.
• Tedgui A, Mallat Z. Cytokines in atherosclero- sis: Pathogenic and regulatory pathways. Physi- ological Reviews 2006; 86: 515-81.
• Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of in- terleukin-6 in human disease. Ann Intern Med ; 128: 127-37. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interluekin-8 protein and gene expression in human arterial atherosclerotic wall. Atheroscle- rosis 1996; 127: 263-71.
• Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascu- lar events: results from the Health ABC study. Circulation 2003; 108: 2317-22.
• Liu Y, S.Y. Berthier-Schaad MD, Fallin, NE, et al. IL-6 Haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic di- alysis cohort. J Am Soc Nephrol 2006; 17: 863-
• Cushman M, Arnold AM, Psaty BM et al. C- reactive protein and the 10-year incidence of co- ronary heart disease in older men and women: the cardiovascular health study. Circulation ; 112: 25-31. Khera A, de Lemos JA, Peshock RM et al. Rela- tionship between C-reactive protein and subcli- nical atherosclerosis: the Dallas Heart Study. Circulation 2006;113: 38-43.
• Boekholdt SM, Hack CE, Sandhu MS et al. C- reactive protein levels and coronary artery dis e- ase incidence and mortality in apparently h e- althy men and women: the EPIC-Norfolk pros- pective population study 1993-2003. Atherosc- lerosis 2006; 187; 415-22.
• Zebrack JS, Muhlestein JB, Horne BD, Ander- son JL; Intermountain Heart Collaboration Study Group. C reactive protein and angiograp- hic coronary artery disease: independent and additive predictors of risk in subjects with angi- na. J Am Coll Cardiol 2002; 39: 632-7.
• Niccoli G, Biasucci LM, Biscione C, et al. In- dependent prognostic value of Creactive protein and coronary artery disease extent in patients af- fected by unstable angina. Atherosclerosis ;196:779-85. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Eng J Med 1997; 336: 973-9.
• Memon L, Spasojevic Kalimanovska V, Boga- vac-Stanojevıc N, et al. Assosiciation of C- recative protein with the presence and extent of angiographically verified coronary artery disea- se. Tohoku J Exp Med 2006; 209: 197-206.